Skip to content
value.today

Codexis, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $158 M to $710 M, median $348 MPrice to bookPrice to book of Biotechnology: $157 M to $623 M, median $230 M$0 M$192 M$384 M$575 M$767 MMarket value $140 M

Your own DCF model

A full discounted-cash-flow model of Codexis, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Codexis, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Codexis, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.1×1.6×revenue $70 M$158 M to $710 M85
Price to book3.1× / 4.5× / 12.3×2.8×book equity $51 M$157 M to $623 M70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Codexis, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

1.8×

Now below its median of 3.6×, in the bottom quarter of its range; range 1.4× to 24.1× over 29 months.

0×6×12×18×24×2020202120222023202420252026Price to sales 2×Median 4×

Price to book

2.8×

Now below its median of 3.4×; range 1.4× to 16.6× over 29 months.

0×4×8×12×17×2020202120222023202420252026Price to book 3×Median 3×

as of Oct 26, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 26, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$70 M$-44 M$-19 M$4 M$-24 M$-11 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$59 M$-65 M$-49 M$4 M$-54 M$10 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$70 M$-76 M$-53 M$4 M$-57 M$-65 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$139 M$-34 M$11 M$8 M$3 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$105 M$-21 M$-14 M$14 M$-28 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$69 M$-24 M$-16 M$4 M$-20 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $140 M on Oct 26, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.